Benenden Hospital, a private hospital near Cranbrook in Kent, has recently celebrated treating over 500 patients with Arthrosamid®, a long-lasting[1,2] hydrogel injection to help patients suffering from knee osteoarthritis. The hospital is the first in the UK to achieve this milestone.
Benenden Hospital launched the service in 2024, offering suitable patients the non-surgical minimally invasive treatment, which involves injecting a hydrogel directly into the knee joint, helping to reduce pain and improve mobility. It offers an effective alternative for those with mild to moderate knee degeneration who may not yet require surgery.
To celebrate the milestone, Consultant Orthopaedic Surgeons Mr Alex Chipperfield and Mr Matthew Oliver, Hospital Director Claire Harley and Director of Clinical Services Ali Turner were joined by members of the hospital’s Theatre, Pharmacy, Private Patients and marketing teams and representatives from developer and manufacturer Contura Orthopaedics for a presentation and cake-cutting.
Claire Harley, Hospital Director, said: “This is a phenomenal milestone for our all our teams involved, from Theatres to Pharmacy and Outpatients. It is a true multidisciplinary approach, and they have worked incredibly hard to collectively deliver a service that has had an enormous impact on the quality of life for hundreds of people.
“This landmark number reflects the very high standards of care and quality of patient experience we offer. The Contura team have been fabulous to work with, and I am immensely proud of our staff and consultants and thank them for the expertise and commitment they brought to this success.”
Alex Chipperfield, Medical Director and Consultant Orthopaedic Surgeon, said: “Arthrosamid® feels like a generational product. I have been in orthopaedics for 30 years and do not recall another treatment that has resonated this much and triggered such interest from both clinicians and patients. Arthrosamid® is supported by solid clinical evidence and the results are reproducible in the real world. It’s a powerful treatment against knee pain and arthritis. It is a privilege to offer this non-surgical injection and to work in partnership with Contura to deliver our 500th case.”
Rakesh Tailor, CEO of Contura Orthopaedics Ltd, added: “We’re thrilled that Benenden Hospital has reached this incredible milestone.
“At Contura Orthopaedics, our mission has always been to reach as many patients as possible with this transformative treatment. The impact of knee osteoarthritis is huge – it’s the fastest growing cause of disability worldwide[3] – and it’s debilitating for so many people. Until recently, the only option for patients was full knee replacement, a surgery which can be daunting, with long recovery times that have a real impact on work and family life.
“Backed by decades of research,[4] Arthrosamid® provides long-lasting, proven pain relief for knee OA,[1,2] without surgery. The latest data show that Arthrosamid® pain relief is maintained for up to five years after a single treatment session.[1,2]
“It’s an honour to be able to celebrate this achievement alongside the whole team at Benenden Hospital and we look forward to continuing our journey together to redefine treatment for knee osteoarthritis.”
For more information about Arthrosamid®, visit https://www.benendenhospital.org.uk/ or https://arthrosamid.com/
References
1. Bliddal, H., et al. (2025). 5-Year Follow-up. Presented at EKS 2025, Copenhagen.
2. Henriksen, M. (2026). Five‑year extension study. J Orthop Surg Res, 21:43.
3. Neogi, T. (2013) The epidemiology and impact of pain in osteoarthritis. Osteoarthritis and Cartilage. Vol 21 (9): 1145-53. DOI:10.1016/j.joca.2013.03.018
4. Data on file
Source and image submitted by Arthrosamid
